Cargando…

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

A JAK2(V617F) mutation is found in approximately 55% of patients with essential thrombocythemia (ET), and represents a key World Health Organization diagnostic criterion. This hypothesis-generating study (NCT01352585) explored the impact of JAK2(V617F) mutation status on treatment response to anagre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cascavilla, Nicola, De Stefano, Valerio, Pane, Fabrizio, Pancrazzi, Alessandro, Iurlo, Alessandra, Gobbi, Marco, Palandri, Francesca, Specchia, Giorgina, Liberati, A Marina, D’Adda, Mariella, Gaidano, Gianluca, Fjerza, Rajmonda, Achenbach, Heinrich, Smith, Jonathan, Wilde, Paul, Vannucchi, Alessandro M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441358/ https://www.ncbi.nlm.nih.gov/pubmed/26028965 http://dx.doi.org/10.2147/DDDT.S79576

Ejemplares similares

The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
por: Birgegård, Gunnar
Publicado: (2016)

Anagrelide‐induced pericardial effusion in a patient with essential thrombocythemia
por: Song, David, et al.
Publicado: (2023)

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders
por: Palmblad, Jan, et al.
Publicado: (2008)

Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review
por: Sugawara, Masafumi, et al.
Publicado: (2022)

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study
por: Birgegård, Gunnar, et al.
Publicado: (2018)

Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report
por: Lim, Young-Hyo, et al.
Publicado: (2010)

Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia
por: Gotic, Mirjana, et al.
Publicado: (2020)

Essential thrombocythemia treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France
por: Rey, Jérôme, et al.
Publicado: (2014)

Leg Ulcers Associated with Anagrelide
por: Oskay, Tuba, et al.
Publicado: (2021)

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting
por: Ito, Tomoki, et al.
Publicado: (2019)

Association of Platelet Thromboxane Inhibition by Low‐Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia
por: Tosetto, Alberto, et al.
Publicado: (2021)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment
por: Byun, Ja Min, et al.
Publicado: (2022)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
por: De Stefano, Valerio, et al.
Publicado: (2018)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Anagrelide-Induced Supraventricular Tachycardia: A Case Report
por: Badar, Faraz, et al.
Publicado: (2022)

The new WHO classification for essential thrombocythemia calls for revision of available evidences
por: Barbui, Tiziano, et al.
Publicado: (2020)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Chronic urticaria reveals JAK2V617F positive essential thrombocythemia
por: Albanesi, Marcello, et al.
Publicado: (2021)

Patients with ≥ 20 × 10(9)/L Platelets at Baseline May Have a Prompt Response to Romiplostim During the Early Phase of Treatment: an Italian Single-Institution Experience
por: Baldini, Simone, et al.
Publicado: (2012)

Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide
por: Gaitanis, Georgios, et al.
Publicado: (2018)

Oral squamous cell carcinoma with essential thrombocythemia and positive JAK2 (V617F) mutation
por: Rahman, Kurnia H., et al.
Publicado: (2021)

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia
por: Abdelghani, Maroua, et al.
Publicado: (2022)

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2023)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets
por: Miyashita, Naohiro, et al.
Publicado: (2019)

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
por: Mora, Barbara, et al.
Publicado: (2019)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
por: Yönal, İpek, et al.
Publicado: (2016)

Cerebral Venous Sinus Thrombosis as the First Manifestation of JAK2(V617F)-positive Essential Thrombocythemia
por: Chen, Wei-Bi, et al.
Publicado: (2018)

Immune Thrombocytopenia and JAK2V617F Positive Essential Thrombocythemia: Literature Review and Case Report
por: Sobas, M. A., et al.
Publicado: (2017)

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
por: Silver, Richard T., et al.
Publicado: (2019)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

Lung Clear “Sugar” Cell Tumor and JAK V617F Positive Essential Thrombocythemia: a Simple Coincidence?
por: Yazak, Volkan, et al.
Publicado: (2013)

Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
por: Ji, Liying, et al.
Publicado: (2017)

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia
por: Vu, Hoang Anh, et al.
Publicado: (2019)

JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia: A case report
por: Oda, Yasuhiro, et al.
Publicado: (2019)

Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera
por: Yikilmaz, Aysun Şentürk, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b3kbsm1ekva6o5dlp9uenif261